Inducible resistance to high levels of the glycopeptide antibiotics vancomycin and teicoplanin in Enterococcus faecium BM4147 is mediated by the 34-kb plasmid pIP816 (8) . The van gene cluster of pIP816 comprises five genes, vanR, vanS, vanH, vanA, and vanX, that are necessary and sufficient for regulated expression of glycopeptide resistance (1) . The vanR and vanS genes encode a two-component regulatory system that activates transcription of vanH, vanA, and vanX in response to the presence of vancomycin in the culture medium (1) . The VanH dehydrogenase encoded by vanH (2) catalyzes the stereospecific reduction of various 2-keto acids to form the corresponding D-2-hydroxy acids (4) . The vanA gene encodes an enzyme, VanA, that is related to D-alanine:D-alanine ligases from Escherichia coli (5) but that displays a broader substrate specificity (3, 4) . In addition to synthesis of dipeptides, VanA catalyzes ester bond formation between D-alanine (D-Ala) and D-2-hydroxy acids (3, 4) . The enzyme favors incorporation of substrates with an ethyl side chain at the C-terminal position of dipeptides and depsipeptides, whereas D-Ala is incorporated at the N terminus. The vanX gene encodes a protein, VanX, of unknown function that is required for resistance (1) .
In crude extracts of E. faecium BM4147, VanA catalyzes ester bond formation between D-Ala and the D-2-hydroxy acid products of VanH; the resulting depsipeptides are incorporated onto the UDP-muramyl tripeptide by the D-Ala-D-Ala adding enzyme (4) . Thus, the catalytic properties of VanH and VanA suggest that these enzymes can mediate in vivo incorporation of a D-2-hydroxy acid at the C-terminal position of peptidoglycan precursors by the putative biosynthetic pathway described in Fig. 1A . However, VanA condenses D-Ala with D-2-hydroxybutyrate or D-2-aminobutyrate with similar catalytic efficiencies (4), suggesting an alternative pathway for the synthesis of peptidoglycan precursors (Fig. 1B) Vancomycin inhibits cell wall synthesis by formation of a complex with the D-Ala-D-Ala termini of peptidoglycan precursors in the outer surface of the bacterial membrane (6, 9) . Measurements of vancomycin affinity for peptidoglycan precursor analogs indicated that the D-Ala residue at the C-terminal position is essential for the stability of the complex (10) . Substitution of the NH group of the amide D-Ala-D-Ala linkage by an oxygen in a D-Ala-D-lactate ester linkage leads to >1,000-fold lower binding by vancomycin (4) . Similarly, substitution of a methyl by an ethyl side chain (D-Ala versus D-2-aminobutyrate) reduced more than 300-fold the binding of the antibiotic to precursor analogs (4) .
Results of these in vitro investigations have established that the vancomycin resistance of E. faecium BM4147 is due to the production of peptidoglycan precursors that bind the antibiotic with reduced affinity (4). However, the actual D-Ala substituent incorporated in vivo could not be identified because of the relatively broad substrate specificity of VanA, VanH, and the D-Ala-D-Ala adding enzyme. Synthesis of a depsipeptide precursor (Fig. 1A ) was considered to be the most likely pathway mainly because, in contrast to VanA, the D-Ala:D-Ala ligase from susceptible enterococci or E. coli does not catalyze ester bond formation (4) . The aim of the present study was to confirm that depsipeptide synthesis is the actual pathway for the peptidoglycan precursor assembly in resistant cells and to identify in vivo the VanA substrates that allow cell wall synthesis in the presence of vancomycin. The pathway in Fig. 1A implies that VanH synthesizes a 2-keto acid from a 2-hydroxy acid, whereas in the pathway in Fig. 1B , VanH catalyzes the reverse reaction and produces a 2-hydroxy acid. To determine whether VanH functions in vivo by producing a 2-keto or a 2-hydroxy acid, we performed an assay to determine whether either of these compounds, when added to the culture medium, could compensate for the insertional inactivation of the vanH gene.
Plasmid pAT80, which confers vancomycin resistance, was constructed by cloning the van gene cluster of pIP816 into the shuttle vector pAT29 (1). Derivatives of pAT80 carrying the aphA-1 kanamycin resistance gene inserted into vanH (pAT83), vanA (pAT84), or vanX (pAT85) do not confer resistance to the antibiotic (1). The MICs of vancomycin for E. faecalis JH2-2 (7) and derivatives harboring plasmids pAT80, pAT83, pAT84, and pAT85 were deter-ANTIMICROB. AGENTS CHEMOTHER. (Table 1 ). The acids did not interfere with the inhibition of cell wall synthesis by vancomycin in the susceptible host E. faecalis JH2-2. The MIC of vancomycin for JH2-2/pAT83 (vanHQaphA-1) was not modified by 2-ketobutyrate, but DL-2-hydroxybutyrate (100 mM) raised the MIC from 1 to 1,024 pug/ml. This effect was not observed with JH2-2/pAT84 (vanAO4aphA4-1).
These results indicate that in vivo the role of VanH is the production of a D-2-hydroxy acid and that VanA-mediated incorporation of D-2-hydroxybutyrate at the C-terminal position of peptidoglycan precursors allows cell wall synthesis in the presence of vancomycin (Fig. 1A) . In agreement with this notion, 100 mM D-2-aminobutyrate did not permit the growth of JH2-2/pAT83 (vanHQaphA-1) in the presence of vancomycin (data not shown). In addition, purified VanX did not bind pyridoxal phosphate and did not possess transaminase activity in the presence of all 20 naturally occurring amino acids (14) .
Since D-2-hydroxybutyrate did not compensate for the insertional inactivation of the vanX gene ( between D-Ala and D-lactate at about a 14-fold lower catalytic efficiency (4). This hydroxy acid restored the vancomycin resistance of JH2-2/pAT83 (vanHQaphA-1) at about a fivefold lower concentration than that required by D-2-hydroxybutyrate (Table 1) . In E. faecalis, the homofermentative pathway for hexose dissimilation leads to the production of L-lactate from pyruvate (13) . Thus, pyruvate is expected to be available for the synthesis of D-lactate by VanH. Reduction of pyruvate is efficiently catalyzed by the purified enzyme (4). These observations suggest that D-lactate is probably the D-Ala substituent present at the C-terminal position of peptidoglycan precursors of enterococci that are resistant to high levels of glycopeptides.
